• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 11:28:21 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NTUS alert in real time by email
    SC 13G/A 1 tv01457-natusmedicalinc.htm SCHEDULE 13G/A natusmedicalinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 6)*

    Name of issuer:  Natus Medical Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  639050103

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  639050103

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    47,378

    7.  SOLE DISPOSITIVE POWER

    2,715,269

    8.  SHARED DISPOSITIVE POWER

    73,733

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,789,002

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.23%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Natus Medical Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    1501 Industrial Road
    San Carlos, CA 94070

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    639050103

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    2,789,002

      (b) Percent of Class:

    8.23%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  47,378

    (iii)  sole power to dispose of or to direct the disposition of:  2,715,269

    (iv)  shared power to dispose or to direct the disposition of:  73,733

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $NTUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTUS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NTUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Route 92 Medical Announces Appointment of Jonathan Kennedy as Chief Financial Officer

    SAN MATEO, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Jonathan Kennedy to the role of Chief Financial Officer. In this role, Jonathan will be responsible for overseeing all financial management for the company, reporting directly to Chief Executive Officer Tony Chou. "Route 92 Medical's technology offers uniquely disruptive solutions in the rapidly growing stroke treatment market. The company is well-positioned for long-term growth, continued product innovation, and meaningful improvements in patient outc

    9/18/23 9:00:00 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Novanta Set to Join S&P MidCap 400; Six Flags Entertainment to Join S&P SmallCap 600

    NEW YORK, July 21, 2022 /PRNewswire/ -- Novanta Inc. (NASD: NOVT) will replace Six Flags Entertainment Corp. (NYSE:SIX) in the S&P MidCap 400, and Six Flags will replace Natus Medical Inc. (NASD: NTUS) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 26. ArchiMed acquired Natus Medical in a deal that closed today. Six Flags Entertainment is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 26, 2022 S&P MidCap 400 Addition Novanta NOVT Information Technology S&P MidCap 400

    7/21/22 6:36:00 PM ET
    $NOVT
    $NTUS
    $SIX
    Industrial Machinery/Components
    Miscellaneous
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value

    MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock. "ArchiMed's mix of operational, medical, scientific and financial expertise will help us continue

    7/21/22 9:13:26 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Schroeder Alice D. returned $750,601 worth of shares to the company (22,406 units at $33.50), closing all direct ownership in the company (for withholding tax)

    4 - NATUS MEDICAL INC (0000878526) (Issuer)

    7/21/22 5:25:24 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4: Moore Bryant M returned $338,819 worth of shares to the company (10,114 units at $33.50), closing all direct ownership in the company (withholding obligation)

    4 - NATUS MEDICAL INC (0000878526) (Issuer)

    7/21/22 5:22:51 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4: Levine Joshua returned $1,252,464 worth of shares to the company (37,387 units at $33.50), closing all direct ownership in the company to cover taxes

    4 - NATUS MEDICAL INC (0000878526) (Issuer)

    7/21/22 5:20:45 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    SEC Filings

    View All

    SEC Form 15-12G filed by Natus Medical Incorporated

    15-12G - NATUS MEDICAL INC (0000878526) (Filer)

    8/1/22 4:09:00 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Natus Medical Incorporated

    EFFECT - NATUS MEDICAL INC (0000878526) (Filer)

    7/25/22 12:15:44 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Natus Medical Incorporated

    EFFECT - NATUS MEDICAL INC (0000878526) (Filer)

    7/25/22 12:15:29 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    Leadership Updates

    Live Leadership Updates

    View All

    Route 92 Medical Announces Appointment of Jonathan Kennedy as Chief Financial Officer

    SAN MATEO, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Jonathan Kennedy to the role of Chief Financial Officer. In this role, Jonathan will be responsible for overseeing all financial management for the company, reporting directly to Chief Executive Officer Tony Chou. "Route 92 Medical's technology offers uniquely disruptive solutions in the rapidly growing stroke treatment market. The company is well-positioned for long-term growth, continued product innovation, and meaningful improvements in patient outc

    9/18/23 9:00:00 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Natus Medical Announces Executive Transition

    Thomas J. Sullivan Appointed President & Chief Executive Officer No Change To 4th Quarter Guidance PLEASANTON, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointment of Thomas J. Sullivan as President & Chief Executive Officer effective December 27, 2021 and a focus on long-term growth. Earlier this year, the Board of Directors engaged a strategic consulting firm to assist it in developing a strategy to build upon Natus' market leading p

    12/17/21 4:01:00 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    Financials

    Live finance-specific insights

    View All

    ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value

    MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock. "ArchiMed's mix of operational, medical, scientific and financial expertise will help us continue

    7/21/22 9:13:26 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50 per share in cash

    Highlights: •        Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value•        Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that it has entered into a definitive agreement to be acquired by an affiliate of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry for app

    4/18/22 7:00:00 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Natus Medical to Hold 2022 First Quarter Financial Results Conference Call on May 6th

    PLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domes

    4/1/22 4:10:00 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Natus Medical Incorporated (Amendment)

    SC 13G/A - NATUS MEDICAL INC (0000878526) (Subject)

    2/2/22 9:06:01 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Natus Medical Incorporated

    SC 13G - NATUS MEDICAL INC (0000878526) (Subject)

    1/19/22 7:51:36 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - NATUS MEDICAL INC (0000878526) (Subject)

    2/10/21 11:28:21 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care